Harnessing Genomics and Molecular Profiling in ER-Positive BC for New Therapies

Summary

Genomic analysis and molecular profiling identified mutations and translocations in ER+ breast cancer that are targets for genome-directed therapeutics. ESR1 mutations and translocations contribute to endocrine therapy resistance. Novel pharmacologic approaches have successfully treated ESR1 Y537 mutation-driven resistance, mutant HER2 tumors, and wild-type RB and TP53 tumor suppressor function in preclinical and clinical work.

  • genome-directed therapeutics
  • estrogen receptor-positive
  • endocrine therapy
  • resistance
View Full Text